Foretinib (CAS 849217-64-7)

Foretinib is a multi-targeted receptor tyrosine kinase (RTK) inhibitor with potent activity against MET and VEGFR2, among other kinases. As an inhibitor, it primarily functions by binding to the ATP-binding sites of these enzymes, effectively blocking their phosphorylation and subsequent signaling pathways that are critical for cell proliferation and angiogenesis. This mechanism of action places Foretinib at the forefront of research focusing on the inhibition of tumor growth and metastasis, particularly in cancers where MET and VEGFR2 play significant roles in disease progression. In oncological research, Foretinib′s ability to target multiple kinases simultaneously is valuable for studying complex signaling networks and offers a promising avenue for exploring novel anti-cancer strategies. Its role extends beyond merely inhibiting tumor growth, as it also provides insights into the molecular mechanisms underlying cancer development and the potential for targeting multiple pathways to overcome resistance to single-targeted therapies.